vgl101
Generic: iluzanebart·Code: VGL101
vgl101: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Vigil Neuroscience, Inc. (VIGL) | Phase 2 |
Clinical Trials (1)
A Phase 2 Safety, Tolerability, and Proof-of-Concept Study of VGL101 in Patients With Adult-Onset Leukoencephalopathy With Axonal Spheroids and Pigmented Glia (ALSP) (The Ignite Study)
Frequently asked questions
Who is developing vgl101?
vgl101 is being developed by Vigil Neuroscience, Inc..
How many clinical trials involve vgl101?
BioSniper tracks 1 clinical trial involving vgl101.
Get deeper analysis on vgl101
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis